1. Invasive treatment is superior to conservative management for patients with NSTEMI based on multiple randomized controlled trials. 2. For high-risk patients based on risk scores like TIMI and GRACE, an immediate invasive approach within 2 hours is recommended to reduce death and myocardial infarction rates. 3. Biomarkers, recurrent ischemia, ECG changes, and hemodynamics help determine which patients should undergo early invasive treatment versus delayed invasive treatment.